Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 1998

View Archived Issues

Protein farnesyltransferase inhibitors disclosed by Schering-Plough

COX-2 inhibitors under study at Abbott

Interneuron: FY 1997 highlights

New carbapenems in development at Takeda

New antifungal antibiotic TKR-842 from Takara Shuzo

PLA2 inhibitors described by Santen

BioChem Pharma/Scriptgen conclude licensing and equity agreements

Yamanouchi: Six-month 1998 highlights

Efficacy of muscle relaxant established in preclinical models

CoCensys and MGH expand license for migraine treatment technology

Company Profile: Shaman

ABX-IL-8 slated to enter clinical testing

Heparinase III efficacy established in preclinical model

New vitamin D conjugates disclosed by Clarion

New NMDA/AMPA antagonists synthesized at Merck & Co.

Selective dopamine D3 ligands revealed by Neurogen

New AIDS treatment candidates disclosed by Vertex

New tachykinin antagonists from Schering-Plough

Arris acquisition of Sequana nears completion

FDA clears Optison

Bayer announces copromotion agreement for cerivastatin

Efficacy of recombinant hirudin demonstrated in patients with DIC

Vasoflux preclinical data presented at major hematology congress

Phase II results presented for BB-10010

Flocor enters phase I for ACS

Vical receives patent protection for lipid-mediated DNA vaccines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...